CelLBxHealth plc (FRA:DWV)

Market Cap	15.75M -62.5%
Revenue (ttm)	3.06M +29.6%
Net Income	-18.41M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	0.0135
Previous Close	0.0135
Day's Range	0.0135 - 0.0135
52-Week Range	0.0005 - 0.1890
Beta	n/a
RSI	54.85
Earnings Date	Jun 1, 2026

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1994
• Employees: 119
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DWV

Financial Performance

In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.

Financial numbers in GBP